Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W T Beck

Showing results (51-60 of 103) with videos related to

Pageof 11
Sort By:
Biochemistry|May 1, 1990
Decreased nuclear matrix DNA topoisomerase II in human leukemia cells resistant to VM-26 and m-AMSAD J Fernandes, M K Danks, W T Beck
Cancer Research|June 1, 1979
Altered surface membrane glycoproteins in Vinca alkaloid-resistant human leukemic lymphoblastsW T Beck, T J Mueller, L R Tanzer
Cancer Research|January 15, 1988
Cytogenetic and molecular characterization of tumors in nude mice derived from a multidrug-resistant human leukemia cell lineA B Hill, W T Beck, J M Trent
Cancer Research|September 1, 1991
Characterization of multidrug resistance by fluorescent dyesD Kessel, W T Beck, D Kukuruga, et al.
Biotechniques|December 24, 1998
Overexpression of human DNA topoisomerase II alpha by fusion to enhanced green fluorescent proteinY Y Mo, K A Ameiss, W T Beck
Advances in Enzyme Regulation|January 1, 1990
Structural characteristics of compounds that modulate P-glycoprotein-associated multidrug resistanceH L Pearce, M A Winter, W T Beck
Biochemical and Biophysical Research Communications|September 26, 1972
The in vivo stimulation of rat liver ornithine decarboxylase activity by dibutyryl cyclic adenosine 3',5'-monophosphate, theophylline and dexamethasoneW T Beck, R A Bellantone, E S Canellakis
Cancer Research|September 1, 1986
Differentiation and the multiple drug resistance phenotype in human leukemic cellsW T Beck, M C Cirtain, R A Ashmun, et al.
Cancer Research|August 15, 1991
Decreased DNA topoisomerase II in daunorubicin-resistant Ehrlich ascites tumor cellsE Friche, M K Danks, C A Schmidt, et al.
Cancer Research|August 1, 1992
DNA topoisomerase II immunostaining in human leukemia and rhabdomyosarcoma cell lines and their responses to topoisomerase II inhibitorsJ S Wolverton, M K Danks, B Granzen, et al.
Pageof 11

Showing results (51-60 of 103) with videos related to

Sort By:
Pageof 11
Biochemistry|May 1, 1990
Decreased nuclear matrix DNA topoisomerase II in human leukemia cells resistant to VM-26 and m-AMSAD J Fernandes, M K Danks, W T Beck
Cancer Research|June 1, 1979
Altered surface membrane glycoproteins in Vinca alkaloid-resistant human leukemic lymphoblastsW T Beck, T J Mueller, L R Tanzer
Cancer Research|January 15, 1988
Cytogenetic and molecular characterization of tumors in nude mice derived from a multidrug-resistant human leukemia cell lineA B Hill, W T Beck, J M Trent
Cancer Research|September 1, 1991
Characterization of multidrug resistance by fluorescent dyesD Kessel, W T Beck, D Kukuruga, et al.
Biotechniques|December 24, 1998
Overexpression of human DNA topoisomerase II alpha by fusion to enhanced green fluorescent proteinY Y Mo, K A Ameiss, W T Beck
Advances in Enzyme Regulation|January 1, 1990
Structural characteristics of compounds that modulate P-glycoprotein-associated multidrug resistanceH L Pearce, M A Winter, W T Beck
Biochemical and Biophysical Research Communications|September 26, 1972
The in vivo stimulation of rat liver ornithine decarboxylase activity by dibutyryl cyclic adenosine 3',5'-monophosphate, theophylline and dexamethasoneW T Beck, R A Bellantone, E S Canellakis
Cancer Research|September 1, 1986
Differentiation and the multiple drug resistance phenotype in human leukemic cellsW T Beck, M C Cirtain, R A Ashmun, et al.
Cancer Research|August 15, 1991
Decreased DNA topoisomerase II in daunorubicin-resistant Ehrlich ascites tumor cellsE Friche, M K Danks, C A Schmidt, et al.
Cancer Research|August 1, 1992
DNA topoisomerase II immunostaining in human leukemia and rhabdomyosarcoma cell lines and their responses to topoisomerase II inhibitorsJ S Wolverton, M K Danks, B Granzen, et al.
Pageof 11